Name (Synonyms) | Correlation | |
---|---|---|
drug2919 | Thymosin+standard treatment Wiki | 1.00 |
drug2022 | PD-1 blocking antibody+standard treatment Wiki | 1.00 |
drug1560 | Leronlimab (700mg) Wiki | 0.71 |
drug2176 | Placebos Wiki | 0.24 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Sepsis, including viral infections, are major causes of death worldwide. Studies show that in 2017, the number of sepsis patients worldwide reached as high as 48.9 million, of which 11 million patients died. Studies in China also showed that more than 1 million patients died of sepsis in 2015. Previous studies have suggested that sepsis are often secondary to excessive inflammatory response syndrome. However, treatment measures targeting excessive inflammatory response failed to effectively improve the prognosis of patients. PD-1 and PD-L1 are key mediators in T cell depletion in sepsis patients. Therefore, the investigators try to performe a clinical research to investigate the efficacy of PD-1 and thymosin in patients with severe pneumonia associated with lymphocytopenia in 2019 novel coronavirus infection.
Description: proportion of lung injury score decreased 1 or more points
Measure: lung injury score Time: 7 daysDescription: lymphocyte counts at day 7, 14 and 28 after randimization
Measure: absolute lymphocyte counts Time: 7, 14 and 28 daysDescription: serum level of CRP, PCT and IL-6 at day 3,7 and 14 after randimization
Measure: serum level of CRP, PCT and IL-6 Time: 3, 7 and 14 daysDescription: SOFA score at Day 7, with scores range from 0 to 24 and higher score means worse outcome
Measure: SOFA score Time: 7 daysDescription: died at day 28
Measure: all cause mortality rate Time: 28 days